The company aims to research, discover, develop, manufacture and market pharmaceutical products based on RNA technology. These products are primarily intended to target mitochondrial dysfunction and endoplasmic reticulum (ER) stress to treat a range of diseases, including lung and kidney fibrosis, liver diseases such as alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD), fibrosis, cirrhosis, drug-induced liver damage, ischemia, liver regeneration and radiation damage, as well as all related issues. The company may establish subsidiaries and branches in Switzerland and abroad and participate in other companies in Switzerland and abroad. It may acquire real estate within the limits of the law. It may acquire, hold and dispose of intellectual property rights. The company may also carry out all commercial, financial and other activities that are directly or indirectly related to the purpose of the company.
Outbound Leads by COHAGA